Chris Schott
Stock Analyst at JP Morgan
(4.17)
# 449
Out of 5,141 analysts
154
Total ratings
64.49%
Success rate
9.56%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Maintains: Overweight | $24 → $28 | $24.98 | +12.09% | 5 | Feb 19, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $1,009.52 | +28.77% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $779.67 | +21.85% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $34.22 | +2.28% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $14.97 | +20.24% | 14 | Dec 15, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $8.10 | +48.15% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $128.78 | +55.30% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $635.66 | +21.92% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $224.81 | +15.65% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $151.40 | -0.92% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $14.50 | -3.45% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $192.03 | -8.87% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $45.12 | -6.91% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $374.75 | -27.95% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $26.65 | +27.58% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $122.26 | +2.24% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $15.92 | -12.06% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.63 | +574.85% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.13 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $60.66 | +28.59% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.38 | +249,900.00% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.30 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $23.22 | +115.33% | 3 | Nov 2, 2018 |
Elanco Animal Health
Feb 19, 2026
Maintains: Overweight
Price Target: $24 → $28
Current: $24.98
Upside: +12.09%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $1,009.52
Upside: +28.77%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $779.67
Upside: +21.85%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $34.22
Upside: +2.28%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $14.97
Upside: +20.24%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $8.10
Upside: +48.15%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $128.78
Upside: +55.30%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $635.66
Upside: +21.92%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $224.81
Upside: +15.65%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $151.40
Upside: -0.92%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $14.50
Upside: -3.45%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $192.03
Upside: -8.87%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $45.12
Upside: -6.91%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $374.75
Upside: -27.95%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $26.65
Upside: +27.58%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $122.26
Upside: +2.24%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $15.92
Upside: -12.06%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.63
Upside: +574.85%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.13
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $60.66
Upside: +28.59%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.38
Upside: +249,900.00%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.30
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $23.22
Upside: +115.33%